Knowledge Center
Explore the Daré Bioscience Knowledge Center for the latest in women’s health innovation, scientific research, and company updates.
Get in-depth articles on breakthroughs, clinical trials, regulatory milestones, and expert insights on reproductive and sexual health.
Featured
Press Release: Daré Bioscience Participates in Virtual Investor “What This Means” Segment
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses FDA clearance of the IND for DARE-HPV, the planned Phase 2 clinical study, and what the program could mean for women’s health.
Press Release: Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
DARE-HPV development supported by $10 million ARPA-H contract; program targets major unmet need with no FDA-approved therapies
Press Release: Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women
Pre-Fulfillment Prescribing Now Available in All 50 States, Supporting National Launch
News + Press Releases
Press Release: Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women’s Health Solutions, and Multiple Near-Term Potential Catalysts
March 26, 2026
News + Press Releases
Press Release: On National Viagra Day, Women Finally Claim Their Turn
DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her
March 23, 2026
News + Press Releases
Press Release: Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026
The webcast will be archived and available for replay until April 9, 2026.
March 20, 2026
News + Press Releases
Press Release: Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth
• Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026
• DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options
• Award reflects Daré’s strategy of leveraging non-dilutive grant funding to advance a deep, differentiated pipeline addressing the most persistent unmet needs in women’s health
March 16, 2026
News + Press Releases
Press Release: Daré Bioscience Participates in Virtual Investor “What This Means” Segment
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses FDA clearance of the IND for DARE-HPV, the planned Phase 2 clinical study, and what the program could mean for women’s health.
March 12, 2026
News + Press Releases
Press Release: Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
DARE-HPV development supported by $10 million ARPA-H contract; program targets major unmet need with no FDA-approved therapies
February 23, 2026
News + Press Releases
Press Release: Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women
Pre-Fulfillment Prescribing Now Available in All 50 States, Supporting National Launch
February 11, 2026
News + Press Releases
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
January 10, 2026
News + Press Releases
Fast Company: Reclaim Women’s Health From Wellness Hype – It’s time to replace the promise of quick fixes with real science.
October 31, 2025
